The Australian pharmaceutical company, Pharmaxis Ltd., has signed an Agreement with Desert Scientific Software for the development and implementation of chemical informatics systems to support Pharmaxis drug discovery.
Desert Scientific Software has licensed to Pharmaxis a range of software tools for small molecule informatics and will create a robust and user-friendly compound inventory system and compound registration system based on these tools. In addition, the parties have entered into an ongoing customisation/consultancy agreement which will provide continuing support and maintenance of the chemical informatics needs of Pharmaxis drug discovery programmes. This is an exciting new development and DesertSci is proud to support Australian pharmaceutical research.
Desert Scientific Software is pleased to announce the release of the 2007 version of its flagship product, Proasis2. The 2007 version includes many new features and enhancements, including:
Proasis2 is the industry's leading protein structure database and visualisation system. Its user community includes 5 of the top 10 global pharmaceutical companies. Through user-driven improvements, Proasis2 continues to be a vital and state-of-the-art tool in drug discovery research.
For more information on Proasis2 or DesertSci's other products and services please go to our website www.desertsci.com or contact us on info@desertsci.com
F. Hoffmann La-Roche, one of the world's leading pharmaceutical research companies, has signed a Joint Venture Agreement with Desert Scientific Software to collaborate on the development of a new generation scoring function based on DesertSci's proprietary software, 'Scorpion'. Staff from both companies will work together developing new methods and know-how in order to bring forward this exciting new technology to a prototype stage. The Agreement is initially for a period of 12 months with the option of 12 monthly extensions dependent on the success of the ongoing collaboration.
This new collaborative agreement extends the present working relationship between DesertSci and F. Hoffmann La- Roche. F. Hoffmann La-Roche currently licenses various software and maintenance/support services from Desert Scientific Software. Both parties are looking forward to this new venture and the myriad possibilities that may develop from the collaboration.
Desert Scientific Software is pleased to announce important improvements in its flagship product, Proasis2. In collaboration with the current user community of global pharmaceutical companies, the following improvements have been made:
For more information on Proasis2 or DesertSci's other products and services please go to our website www.desertsci.com or contact us on info@desertsci.com
Another of the world' s leading pharmaceutical companies has licensed Desert Scientific Software's cutting edge software Proasis2® to complement their global research technology.
This completes another successful year for the Australian based Desert Scientific Software, with two new major licensing deals and four collaborative ventures involving Proasis2.
To date, five of the top ten global pharmaceutical companies license Proasis2®, the industry's best protein structure database and visualization system. In addition to licensing the software, close collaborations ensures Proasis2® meets the needs of its user community, at the cutting edge of drug research.
Proasis2® is a web-based protein structure and visualization tool designed expressly for medicinal chemistry research. In one complete system it combines a superior relational database for storing, retrieving, and searching protein structures important to medicinal chemistry projects with the most intuitive desktop visualization systems for exploring those structures. Proasis2® provides more scientists with better quality data and tools needed to make the right decisions in drug discovery projects.
For more information on Proasis2® or DesertSci's other software products, please see www.desertsci.com
Roche, one of the world's leading healthcare companies, has selected Desert Scientific Software's, Proasis2® as their 3D Protein Structure Database for global research programs.
Desert Scientific Software (DesertSci), a chemo/bioinformatics software company based in Sydney, Australia is pleased to announce the global licensing of their flagship product, Proasis2®, by one of the world's leading healthcare companies, Roche, Basel, Switzerland. Proasis2®, industry's best protein structure database and visualization system, will be used across the entire Roche Pharma research organization to enhance the efficiency of their drug discovery programs. This agreement is in addition to the ongoing collaboration between DesertSci and Roche covering the development of advanced tools for molecular property calculations and molecular modelling.
Proasis2 is a web-based tool designed specifically for drug discovery research. The software allows users to make complex, high quality decisions on Discovery projects by using more complete sets of structural information and leveraging advanced scientific tools, behind an easy-to-use interface.
For more information about DesertSci, please visit our website at www.desertsci.com.
Desert Scientific Software, Sydney, Australia, in collaboration with F. Hoffmann La-Roche have a new paper published in the Journal of Medicinal Chemistry, describing the application of Spinifex. The paper is: 'A Robust Clustering Method for Chemical Structures', M. Stahl, H. Mauser, M. Tsui, N.R. Taylor, J. Med. Chem, 2005, 48 (13), 4358-4366.
The JMedChem paper describes clustering based on finding the largest set of disconnected fragments that two chemical compounds have in common. Spinifex is shown to be the best clustering method compared with other approaches currently in use throughout the pharmaceutical industry. The data sets used in the analysis are available for download allowing other workers to carry out comparisons themselves.
For more information on Spinifex, please go to our Products page.
GlaxoSmithKline has signed a new agreement with Desert Scientific Software, Sydney, Australia, in the area of protein structure database technology.
Desert Scientific Software (DesertSci) will be providing GlaxoSmithKline (GSK) with the Advanced Protein Structure Overlay module for Proasis2®, functionality which was created to suit the needs of experienced molecular modelling users. In addition, the collaboration includes the further development and implementation of customised new features for Proasis2®.
DesertSci announces the release of Spinifex version 2.2 - advanced chemical similarity software.
Spinifex rapidly computes the Maximum Overlapping Set (MOS) of a pair of chemical structures. Molecular comparisons based on the MOS are very useful for clustering chemically related compounds. Highlights of recent advances include:
For more information on Spinifex, go to our Products page
Sanofi-Aventis, the world's 3rd largest pharmaceutical company, has licensed Proasis2®, Desert Scientific Software's protein structure database and visualization system
Desert Scientific Software (DesertSci), a chemo/bioinformatics software company based in Sydney, Australia is pleased to announce the global licensing of their flagship product, Proasis2®, by Sanofi-Aventis. The collaboration includes an on-going development agreement that promises to deliver further enhancements and exciting new features to the system.
Proasis2® delivers the industry's best protein structure database and visualisation system for medicines research. In one complete system it combines a superior relational database for storing, retrieving, and searching structures important to medicinal chemistry projects with the most intuitive desktop visualization system for exploring those structures. Developed in collaboration with a number of global pharmaceutical companies, Proasis2® matches the real requirements of leading edge drug discovery. It empowers medicinal chemists to explore ideas themselves and significantly frees up crystallographers and modellers time so that they can concentrate on their own sophisticated problems in drug discovery.
Desert Scientific Software Pty Ltd (Sydney, Australia) has entered into an agreement with Infocom Corporation (Tokyo, Japan) to market their drug discovery software in the Japanese market.
The agreement, initially for a period of 12 months, will sound out the Japanese market for Desert Scientific Software proprietary chemoinformatics software. DesertSci's products are well established among the top tier pharmaceutical companies in Europe and the US, with 4 of the top 10 companies now using their toolkit software. This agreement provides an exciting opportunity for Desert Scientific Software to expand into a very important market and will help to build long term relationships within the growing Japanese pharmaceutical industry.
Desert Scientific Software's flagship product, Proasis2® is a protein structure database and visualisation system. It provides a fast, comprehensive tool for chemists undertaking drug discovery by hiding routine yet complex computational methods behind an easy- to-use web interface. This is particularly relevant for the medium sized pharmaceutical firms typical in the Japanese market. By using Proasis2®, productivity of the scientific workforce is increased and the time of expert computational chemists is expanded to focus on the more advanced problems faced within the drug discovery projects.
Mr Katsuo Kunugi of Infocom Corporation, said "Infocom is very delighted to have an opportunity to explore the business possibility with Desert Scientific Software. Infocom will be investigating market needs in the Japanese pharmaceuticals industry and accessing the market acceptance of Proasis2® based on the pre-marketing activities."
Infocom Corporation was established in February 1983. Infocom carries out wide-ranging business development centered on the areas of medical services, and drug discovery support and drug information, beginning with genomes with the keyword "drug". In the field of biosciences, in addressing the new "post-genome" era, Infocom aims to further strengthen their business foundation, including expanding solutions in the fields of proteomes and molecular design.
Infocom Corporation contact details for Desert Scientific Software's products: Mr.Syuinichi Ozawa, Bioscience Department, Life Science Division, Mitsui-Kaijou Annex, 3-11 Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-0062, Japan, e-mail : s.ozawa@infocom.co.jp.
DesertSci announces release of Proasis2®, 2004 Version, Second Edition. Highlights of advances include:
DesertSci announces release of Proasis2®, 2004 Version. Highlights of advances include:
Roche, Basel, Switzerland, have agreed on a new collaboration with Desert Scientific Software, Sydney, Australia, in the area of HTS Data Analysis. DesertSci will be providing Roche with a customised HTS Data Analysis Tool that will combine DesertSci's chemical similarity package, Spinifex, with new clustering software and an easy-to-use interface.
Roche also agreed to continue to collaborate with DesertSci on WebStar, an advanced software tool for molecular property and descriptor calculations.
GlaxoSmithKline has licensed Desert Scientific Software's, Proasis2®
Desert Scientific Software (DesertSci), a chemo/bioinformatics software company based in Sydney, Australia is pleased to announce the global licensing of their flagship product, Proasis2®, by GlaxoSmithKline (GSK). The collaboration includes further development and implementation of customised new features.
Proasis2® is a state of the art protein structure database and visualization system. It is a web-based tool designed specifically for drug discovery research. Developed in collaboration with a number of global pharmaceutical companies, the software makes the access to protein structures for molecular visualisation and modelling applications as routine as searching the internet. It empowers chemists to explore their own drug design ideas and increases the productivity of expert modellers.
Dr. Neil Taylor, Founder and Chief Scientific Officer of Desert Scientific Software said "We have a commitment to providing software tools that optimize the efficiency of individual scientists and facilitate the dissemination of expertise within research groups."
DesertSci announces the creation of Advanced Protein Structure Overlay functionality for Proasis2®, designed to suit the needs of experienced molecular modelling users.
Key features:
These new Proasis2® components will be showcased at the upcoming Molecular Modelling meeting, Bioactive Discovery in the New Millenium, in Victoria, Australia, February 2003.
For more information on Proasis2®, go to our Products page
Roche, Basel, Switzerland, have agreed to continue their collaboration with Desert Scientific Software, Sydney, Australia, for the fourth year running. DesertSci will continue to provide Roche with advanced software tools for molecular property calculations and molecular modelling.
Spinifex, a new tool for determining chemical similarity, has been released.
For more information on Spinifex, go to our Products page
Proasis2®, Desert Scientific Software's Protein Structure Database and Visualisation System, is released.
Proasis2® is a protein structure database system for drug discovery developed in collaboration with several major pharmaceutical companies. It facilitates the interpretation of protein-ligand binding affinity through visual representations. The system is able to manage in-house and public domain protein structure data resources. Proasis2® enables researches to: closely examine the key structural features of binding sites; easily overlay multiple complexes for comparing and contrasting ligand binding modes; explore a wide range of non-bonded interactions in binding sites using new methods. Proasis2® makes the most valuable and frequently used molecular modelling tasks as routine as searching the internet. The software runs on various platforms including Silicon Graphics, Linux, and Windows.
For more information on Proasis2®, go to our Products page
The collaboration between Roche, Basel, Switzerland, and Desert Scientific Software, Sydney, Australia, has been arranged to continue for 2002. DesertSci will continue to provide support for Hoffmann La-Roche's WebStar, the global web based chemoinformatics system for the prediction and retrieval of ADME properties for compounds in medicines research, originally developed with DesertSci staff. Futhermore, the agreement will provide Roche scientists with new software for chemical similarity searching based on the detection of maximum common substructures.
AstraZeneca of Mölndal, Sweden, and Desert Scientific Software, Sydney, Australia, have signed a collaboration agreement on the further development of protein structure database technology. Under the agreement, DesertSci will establish a web-based protein structure database and visualisation environment which is closely integrated with AstraZeneca's global Structure-Based Design Platform. The collaboration is to include the licensing of DesertSci's existing software for protein structure database handling and visualistion, Proasis; customisation of those components; the design of a new graphical user interface; and the implementation of new functionality.
AstraZeneca, of Mölndal, Sweden has signed a collaboration agreement with Desert Scientific Software, Sydney, Australia. Under the agreement, DesertSci will provide a web-based interface to existing AstraZeneca software related to CC-DMPK.